// App-Quantinova.ai

: Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Nizar Bahlis

Principal Investigators

  • Meletios A Dimopoulos

  • Darrell J White

  • Lotfi Benboubker

  • Gordon Cook

  • Merav Leiba

  • P. Joy Ho

  • Kihyun Kim

  • Naoki Takezako

  • Philippe Moreau

  • Maria Krevvata

  • Christopher Chiu

  • Xiang Qin

  • Linda Okonkwo

  • Sonali Trivedi

  • Ming Qi

  • Jesus F San-Miguel

Medical Centers

  • National and Kapodistrian University of Athens, Athens, Greece

  • Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Service dHematologie et Therapie Cellulaire, Hopital Bretonneau, Centre Hospitalier Regional Universitaire (CHRU), Tours, France

  • Assuta University Hospital, Faculty of Health Science, Ben-Gurion University of the Negev, Beersheba, Israel

  • Institute of Academic Surgery, Royal Prince Alfred Hospital, Camperdown, Australia

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan

  • University Hospital Hotel-Dieu, Nantes, France

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, CIBERONC, Pamplona, Spain

Locations

  • Canada

  • Greece

  • France

  • United Kingdom

  • Israel

  • Australia

  • Republic of South Korea

  • Japan

  • United States

  • Spain

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved